Equillium (NASDAQ:EQ) Posts Earnings Results, Beats Estimates By $0.06 EPS

Equillium (NASDAQ:EQ) announced its earnings results on Thursday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06, Zacks reports. Equillium had a negative return on equity of 20.68% and a negative net margin of 10.05%. The business had revenue of $4.39 million for the quarter.

Equillium Price Performance

Shares of Equillium stock traded down $0.08 on Friday, hitting $0.41. 222,849 shares of the company’s stock traded hands, compared to its average volume of 360,289. The company has a fifty day moving average of $0.76 and a two-hundred day moving average of $0.80. Equillium has a one year low of $0.39 and a one year high of $2.45. The company has a market capitalization of $14.56 million, a price-to-earnings ratio of -2.94 and a beta of 1.87.

Analyst Upgrades and Downgrades

Separately, Leerink Partners reaffirmed a “market perform” rating and issued a $1.00 price objective (down from $3.00) on shares of Equillium in a research note on Friday.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.